210,884 Shares in CG Oncology, Inc. $CGON Bought by TimesSquare Capital Management LLC

TimesSquare Capital Management LLC purchased a new stake in shares of CG Oncology, Inc. (NASDAQ:CGON) in the second quarter, Holdings Channel reports. The firm purchased 210,884 shares of the company’s stock, valued at approximately $14,983,000.

Several other institutional investors have also added to or reduced their stakes in the company. NFSG Corp bought a new stake in CG Oncology in the 1st quarter worth $34,000. Whittier Trust Co. of Nevada Inc. bought a new position in shares of CG Oncology during the fourth quarter valued at about $27,000. Comerica Bank boosted its holdings in shares of CG Oncology by 100.4% during the fourth quarter. Comerica Bank now owns 1,028 shares of the company’s stock worth $43,000 after purchasing an additional 515 shares during the period. Fifth Third Bancorp purchased a new stake in shares of CG Oncology during the first quarter worth about $74,000. Finally, KBC Group NV bought a new stake in shares of CG Oncology in the first quarter worth about $78,000. Hedge funds and other institutional investors own 26.56% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Royal Bank Of Canada reduced their price target on CG Oncology from $81.00 to $79.00 and set an “outperform” rating on the stock in a report on Friday, August 7th. Wolfe Research began coverage on CG Oncology in a report on Tuesday, May 19th. They issued a “peer perform” rating for the company. Wall Street Zen lowered CG Oncology from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. JPMorgan Chase & Co. boosted their target price on CG Oncology from $91.00 to $96.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Finally, HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of CG Oncology in a report on Wednesday, July 29th. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $83.18.

Insider Buying and Selling at CG Oncology

In other CG Oncology news, Director Leonard E. Post sold 5,000 shares of CG Oncology stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $70.00, for a total transaction of $350,000.00. Following the sale, the director directly owned 5,000 shares of the company’s stock, valued at approximately $350,000. The trade was a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Brian Guan-Chyun Liu bought 371,085 shares of CG Oncology stock in a transaction on Thursday, June 25th. The shares were purchased at an average price of $66.87 per share, for a total transaction of $24,814,453.95. Following the acquisition, the director directly owned 1,886,236 shares in the company, valued at approximately $126,132,601.32. This trade represents a 24.49% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have sold 37,129 shares of company stock valued at $2,663,817. 4.80% of the stock is currently owned by corporate insiders.

CG Oncology Trading Up 2.8%

Shares of CGON opened at $77.11 on Tuesday. The firm’s 50-day moving average price is $69.60 and its 200-day moving average price is $64.91. The firm has a market capitalization of $6.84 billion, a price-to-earnings ratio of -28.67 and a beta of 0.23. CG Oncology, Inc. has a 1-year low of $24.85 and a 1-year high of $79.39.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.24). CG Oncology had a negative net margin of 3,602.68% and a negative return on equity of 25.20%. The company had revenue of $1.16 million for the quarter, compared to analysts’ expectations of $0.36 million. On average, research analysts forecast that CG Oncology, Inc. will post -3.25 EPS for the current fiscal year.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.